In the United States, about 12, 0000 people have been diagnosed with glioblastoma – the most common type of brain cancer. Half of the patients diagnosed with glioblastoma die within 15 months of diagnosis because there are very few effective treatments for this type of brain cancer; in most instances, the disease cannot be cured.
According to Andrew Lassman, MD, chief of neuro-oncology at the Columbia University Irving Medical Center, glioblastoma is one of the most aggressive brain cancers. Even a tumor that is just beginning to grow can cause distressing neurological problems. New therapies have been tried, but the results gave very little chance of survival.
Patients with glioblastoma at Columbia University are hopeful about the new type of clinical trial, as they will be the first ones to be enrolled in the program. This new type of glioblastoma clinical trial aims to develop a promising therapy for the disease.
This new type of clinical trial is called the GBM AGILE. The test also aims to identify new and effective therapies quickly by evaluating drug candidates at the same time rather than testing and evaluating each therapy separately. This new technique is developed because over the years, a lot of new treatments are tested but take years before a clinical trial is proven to be effective.
Like other randomized and controlled trials, GBM AGILE patients will receive experimental treatment and treatment group, but this time, multiple treatment groups can be added without needing a separate protocol. With the GBM AGILE trial, the number of therapies to be tested can be limitless.
Through this process, it is easier to accumulate data that can be useful to the development of new therapies. This will also allow doctors to easily identify therapies that are effective and therapies that do not yield good results.